Company Profile · Healthcare

Zoetis Inc

ZTS · US
Exchange
US
Country
USA
IPO date
Feb 1, 2013
Employees
14,500
Current Price
$78.71
Live · Jun 18, 2026
Fair Buy
≤ $75
Margin-of-safety entry
Baillie Growth Score
47/100
Weak
Intrinsic Value · Three-Tier Range Current price $78.71 Live · Within the conservative intrinsic-value range · significant margin of safety

Composite valuation range · conservative $70–$80 / fair $100–$120 / optimistic $150–$180. At $78.71, Within the conservative intrinsic-value range · significant margin of safety.

At publication $80.23 (May 28, 2026)

No reports on this stock in your language yet.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Market cap$32.39B
Revenue (TTM)$9.53B
EBITDA$4.07B
Profit margin28.04%
ROE67.75%
P/E (TTM)12.67
Forward P/E11.6
PEG1.9
EPS$6.10
Dividend yield2.56%
52-week range$72.38 – $159.30
Analyst target$124.59
Analyst rating4.0 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.